Cover Image

The effect of GLP-1 receptor agonist lixisenatide on experimental diabetic retinopathy

Glucagon-like peptide-1 receptor agonists are effective treatments for type 2 diabetes, effectively lowering glucose without weight gain and with low risk for hypoglycemia. However, their influence on the retinal neurovascular unit remains unclear. In this study, we analyzed the effects of the GLP-1...

Full description

Saved in:
Bibliographic Details
Main Authors: Özer, Kübra (Author) , Kolibabka, Matthias (Author) , Gassenhuber, Johann (Author) , Dietrich, Nadine (Author) , Fleming, Thomas (Author) , Schlotterer, Andrea (Author) , Morcos, Michael (Author) , Wohlfart, Paulus (Author) , Hammes, Hans-Peter (Author)
Format: Article (Journal)
Language:English
Published: November 2023
In: Acta diabetologica
Year: 2023, Volume: 60, Issue: 11, Pages: 1551-1565
ISSN:1432-5233
DOI:10.1007/s00592-023-02135-7
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s00592-023-02135-7
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s00592-023-02135-7
Get full text
Author Notes:Kuebra Oezer, Matthias Kolibabka, Johann Gassenhuber, Nadine Dietrich, Thomas Fleming, Andrea Schlotterer, Michael Morcos, Paulus Wohlfart, Hans-Peter Hammes
Description
Summary:Glucagon-like peptide-1 receptor agonists are effective treatments for type 2 diabetes, effectively lowering glucose without weight gain and with low risk for hypoglycemia. However, their influence on the retinal neurovascular unit remains unclear. In this study, we analyzed the effects of the GLP-1 RA lixisenatide on diabetic retinopathy.
Item Description:Online veröfffentlicht: 9. Juli 2023
Gesehen am 02.09.2024
Physical Description:Online Resource
ISSN:1432-5233
DOI:10.1007/s00592-023-02135-7

Similar Items